Familial natural short sleep mutations reduce Alzheimer pathology in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study.
PubMed 35496999 · doi:10.1016/j.isci.2022.103964
What was done
Researchers crossed mouse models of Alzheimer's disease pathology (tau mice and 5XFAD amyloid mice) with transgenic mouse lines harboring human familial natural short sleep (FNSS) mutations (DEC2-P384R or Npsr1-Y206H). They evaluated the impact of these mutations on hippocampal tau pathology and amyloid-beta plaque deposition at 6 months of age compared to control Alzheimer model mice.
What was found
The abstract reports directional findings without numerical values or p-values. Development of tau pathology was attenuated in the hippocampus of tau mice carrying FNSS mutations. In the 5XFAD model, DEC2-P384R;5XFAD mice and female Npsr1-Y206H;5XFAD mice exhibited significantly fewer amyloid plaques than control mice at 6 months of age.
Why it matters
The findings suggest that genetic mechanisms underlying natural short sleep phenotypes may confer protection against tau and amyloid-beta accumulation, highlighting potential targets for neurodegenerative disease resilience.
Limits
This study was conducted entirely in transgenic mouse models, meaning findings cannot be directly applied to human clinical populations. The abstract provides no exact sample sizes, quantitative effect sizes, variance, or p-values. In addition, the amyloid-reducing effect for the Npsr1 mutation was reported only in female mice, leaving male-specific effects uncharacterized in the abstract.
Cited by
- supports Specific genetic mutations allow certain individuals to function naturally on only 3 to 5 hours of sleep per night.